Whether a product is a food supplement or a medicinal product is not decided by what the manufacturer calls it. It is decided by how the product is presented and what it does, and a wrong call can mean market withdrawal. Getting this right is the first regulatory question for any health-oriented product.
Two routes to medicinal status
Under EU medicines law a product is medicinal either by presentation, where it is described as having properties for treating or preventing disease, or by function, where it can restore, correct or modify physiological functions through a pharmacological, immunological or metabolic action. The Court of Justice has applied these tests case by case, and national authorities, including EOF in Greece, assess each product on its facts.
What the supplement rules forbid
Directive 2002/46/EC provides that labelling, presentation and advertising of food supplements must not attribute to them the property of preventing, treating or curing a human disease, or refer to such properties. Any such statement pushes the product toward medicinal status and creates an enforcement problem at the same time.
A recent clarification from the Court of Justice
In its March 2023 ruling in Landeshauptmann von Wien v Kwizda Pharma, the Court addressed the line between foods for special medical purposes and medicines. Trade reporting summarises it as follows: products offering only a general benefit for disease prevention cannot qualify, and dietary management requires nutritional needs arising from a disease that cannot be met by modifying the normal diet. Food supplements, by contrast, merely supplement the diet. The case concerned a different food category, but the reasoning shows how strictly authorities read the boundary.
Practical risk indicators
- Disease names, symptoms or patient-style testimonials in any material.
- Dose levels or botanical ingredients with a clear pharmacological effect.
- Presentation resembling a medicine, such as dosing schedules for a condition.
- Claims on a website or distributor leaflet that go beyond the label.
How PQRA helps
PQRA assesses borderline risk early, reviews formulations and claims, and prepares the case for the correct pathway, whether that is a food supplement notification or a medicinal product application.


No responses yet